Sana Biotechnology Stock Soars on Positive CAR T-Cell Therapy Results
Sana Biotechnology's stock soared 50% to $7.72 after revealing promising results from its SC291 CAR T-cell therapy at the...
CAR T-cell immunotherapies
FDA Investigates CAR T Drugs, Cabaletta Bio Shares Plummet
In a major blow to Cabaletta Bio, shares of the company plummeted by 32% to $12.72 after the U.S....